Neuronetics Common Stock Total Equity from 2010 to 2026
| STIM Stock | USD 1.56 0.14 9.86% |
Common Stock Total Equity | First Reported 2017-12-31 | Previous Quarter 285 K | Current Value 288 K | Quarterly Volatility 80.3 K |
Check Neuronetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuronetics' main balance sheet or income statement drivers, such as Interest Income of 3.3 M, Depreciation And Amortization of 1.3 M or Interest Expense of 4.4 M, as well as many indicators such as Price To Sales Ratio of 0.58, Dividend Yield of 0.0 or PTB Ratio of 1.89. Neuronetics financial statements analysis is a perfect complement when working with Neuronetics Valuation or Volatility modules.
Neuronetics | Common Stock Total Equity | Build AI portfolio with Neuronetics Stock |
Evaluating Neuronetics's Common Stock Total Equity across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Neuronetics's fundamental strength.
Latest Neuronetics' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Neuronetics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Neuronetics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuronetics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Neuronetics Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 135,623 | |
| Geometric Mean | 25,691 | |
| Coefficient Of Variation | 100.13 | |
| Mean Deviation | 125,763 | |
| Median | 177,000 | |
| Standard Deviation | 135,806 | |
| Sample Variance | 18.4B | |
| Range | 327.6K | |
| R-Value | 0.93 | |
| Mean Square Error | 2.5B | |
| R-Squared | 0.87 | |
| Slope | 25,110 | |
| Total Sum of Squares | 295.1B |
Neuronetics Common Stock Total Equity History
About Neuronetics Financial Statements
Neuronetics investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how Neuronetics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 313.9 K | 329.6 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Neuronetics Correlation against competitors. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuronetics diversify its offerings? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuronetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth 1.013 | Return On Assets | Return On Equity |
Neuronetics's market price often diverges from its book value, the accounting figure shown on Neuronetics's balance sheet. Smart investors calculate Neuronetics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Neuronetics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.